While gonadal and adrenal steroids heavily impact sexual function at the level of the brain, the nervous system also produces its own steroids de novo that may regulate sexual behavior and reproduction. Current evidence points to important roles for neurosteroids in sexual and gendertypical behaviors, control of ovulation, and behaviors that strongly influence sexual interest and motivation like aggression, anxiety and depression. At the cellular level, neurosteroids act through
Neurosteroid Receptor Targets
While peripheral steroids generally influence target tissues via classical nuclear steroid receptors to cause long-term genomic changes, neurosteroids have more immediate, nongenomic effects. Neurosteroids act at G protein-coupled and ligand-gated ion channel membrane receptors to elicit rapid changes that occur within seconds to milliseconds. Glycine receptors, metabotropic sigma type 1 (σ 1 ) receptors and ionotropic glutamate receptors like the N-methyl-D-aspartic acid (NMDA) receptor are among the neuronal receptor targets of neurosteroids (Rupprecht and Holsboer, 1999) (Table 1) .
Neurosteroids can also allosterically modulate and directly activate γ-aminobutyric acid type A (GABA A ) receptors at levels that are found in the brain (Belelli and Lambert, 2005; Gee et al, 1995; Lambert et al, 2003; Reddy, 2004) . In this manner, neurosteroids significantly impact phasic and tonic inhibition of neurons through synaptic and extrasynaptic GABA A receptors, respectively. Through changes in GABA A channel chloride currents, nanomolar levels of 5α-reduced androstanediol, allopregnanolone and THDOC reduce neuronal excitability with a 20 to 200-fold higher efficacy than benzodiazepines and barbiturates (Brot et al, 1997; Gee et al, 1995; Morrow et al, 1987; Weir et al, 2004) . On the other hand, pregnenolone sulfate and DHEA-S antagonize GABA A channel activity (Majewska et al, 1986; Majewska et al, 1990; Majewska and Schwartz, 1987) .
Neurosteroids may also alter neuronal function through plasma membrane-localized estrogen receptors (Chaban et al, 2004) and G protein-coupled membrane progesterone receptors (Zhu et al, 2003) . Other receptor targets include α 1 -adrenergic (Dong et al, 2005) , neuronal nicotinic acetylcholine (nnAchR) (Bertrand et al, 1991; Bullock et al, 1997) and dopamine type 1 (D 1 ) receptors (Table 1) .
Thus, local synthesis and release of neurosteroids can precisely and rapidly alter neuronal function in a manner not achievable by neuroactive steroids infiltrating the nervous system from the serum. In this manner, neurosteroids may regulate key aspects of male and female reproduction.
Neurosteroids and Sexual Function
During follicular development, ovarian estrogen and progesterone regulate folliclestimulating hormone (FSH) and luteinizing hormone (LH) release directly at the anterior pituitary and indirectly by regulating hypothalamic secretion of gonadotropin-releasing hormone (GnRH).
As well, the culminating LH surge which triggers the process leading to ovulation is an estrogen-dependent response. This situation is one example where a peripheral steroid, estrogen, likely acts in a rapid manner similar to neurosteroids.
The release of GnRH for the LH surge also requires progesterone acting through hypothalamic progesterone receptors (Chappell et al, 1999; Chappell and Levine, 2000) . Recent data indicate that the source of this progesterone is astrocytes in the hypothalamus stimulated to produce steroid by activation of estrogen-sensitive membrane receptors by estradiol.
Administration of supraphysiologic amounts of estrogen (50 μg) to ovariectomized (OVX)/adrenalectomized (ADX) rats induces de novo progesterone synthesis specifically in the medial basal hypothalamus and the LH surge through release of GnRH (Micevych et al, 2003; Soma et al, 2005) . Inhibition of hypothalamic progesterone synthesis blocks the LH surge (Micevych et al, 2003) . Importantly, estrogen only stimulates this progesterone synthesis in postpubertal not neonatal astrocytes (Micevych et al, 2007) .
Estrogen also stimulates allopregnanolone synthesis in the hypothalamus and anterior pituitary as shown in OVX animals (Genazzani et al, 2004) . There, allopregnanolone can potentiate activation of post-synaptic GABA A receptors on GnRH neurons of diestrus female mice (Sullivan and Moenter, 2003) . Through activation of these receptors, allopregnanolone induces GnRH release (El-Etr et al, 1995) . The decline in this steroid that occurs with age in the hypothalamus may thus contribute to age-related changes in ovarian function (Genazzani et al, 2004 ).
The facilitory effect of allopregnanolone on GnRH release may be site-specific.
Activation of hypothalamic GABA A receptors by intracerebroventricular (i.c.v.)-delivered allopregnanolone which provides access to the VMN suppresses ovulation (Genazzani et al, 1995) . Sulfated neurosteroids can also regulate GnRH release. DHEA-S inhibits post-synaptic GABA A receptor activation in GnRH neurons of diestrus female mice (Sullivan and Moenter, 2003) while pregnenolone sulfate potentiates glutamate or NMDA-stimulated GnRH release through the NMDA receptor by hypothalamic neurons (El-Etr et al, 2006) .
At the same time, a GABA A receptor modulator and allopregnanolone precursor produced by the pituitary, 3α-hydroxy-4-pregnen-20-one (3αHP), can selectively inhibit basal and GnRH-stimulated FSH secretion in both sexes (Beck et al, 1997; Wiebe et al, 1997; Wiebe and Wood, 1987; Wood and Wiebe, 1989) . This rapid, nongenomic effect is mediated by calcium and protein kinase C signaling pathways utilized by GnRH and is not due to any further metabolism to allopregnanolone Wiebe et al, 1994) .
Thus, neurosteroids may regulate gonadotropin release in both the female and the male.
A further observation whose significance is unclear at the present time is that LH itself can regulate neuronal pregnenolone production (Liu et al, 2007) .
Little else is known about the participation of neurosteroids in male reproduction and sexual differentiation of the brain. Male rats do exhibit higher cerebellar levels of StAR, P450scc and aromatase mRNAs (Lavaque et al, 2006) . The extent to which neurosteroids like 3αHP may affect secretion of FSH or LH is unclear. Unlike in females, estrogen does not induce hypothalamic progesterone production to stimulate GnRH release in castrate ADX males (Micevych et al, 2003) . However, locally produced allopregnanolone may be involved.
Allopregnanolone potentiation of GABA A channel activity reduces basal GnRH release in hypothalamic cultures (Calogero et al, 1998 ). This suppression is selectively overcome by pregnenolone sulfate.
Neurosteroids and Sexual Behavior
Female Sexual Behavior. Emerging data indicate a vital role for neurosteroids in the control of female sexual behaviors that are critical for successful reproduction (King and Lamb, 2006) . Receptive behaviors as shown in rodents require the action of ovarian estrogen on the hypothalamus which increases progesterone receptor number in the ventral portion of the ventromedial nucleus (VMN) (Pfaff D and Schwartz-Giblin S, 1998) . Progesterone then acts through these receptors to facilitate lordosis and appropriate tactile stimulation. Locally produced allopregnanolone may also have a vital role. Participation in paced mating behavior specifically increases levels of allopregnanolone in specific regions of the CNS including the midbrain and hippocampus (Frye et al, 2007) .
Allopregnanolone or THDOC infused into the ventral tegmental area (VTA) enhances and maintains progesterone-facilitated lordosis in estrogen-primed OVX rats and hamsters (Frye and DeBold, 1993; Frye and Gardiner, 1996) . Inhibition of 3βHSD or 5α-reductase activity in the VTA attenuates lordosis and infusion of allopregnanolone into the VTA rescues this behavior (Frye and Vongher, 2001; Petralia et al, 2005) . D 1 and GABA A receptors acting through cAMP pathways in the VTA may be the primary mechanism by which neuronally derived allopregnanolone as well as progesterone may promote this responsiveness (Frye, 2001a; Frye, 2001b; Frye et al, 2004; Petralia and Frye, 2004) .
However, the effect of allopregnanolone on sexual activity is site-specific.
Allopregnanolone levels selectively fluctuate in the ventral medial hypothalamus with the ovarian cycle, with its lowest levels reached at proestrus when sexual receptivity and lordotic behavior coincide with rising serum estrogen and progesterone concentration (Genazzani et al, 1995) .
Intracerebroventricular administration of allopregnanolone suppresses sexual behavior by OVX rats possibly through actions in the VMN (Genazzani et al, 1995; Laconi and Cabrera, 2002) .
This suggests that circulating allopregnanolone (as opposed to neurosteroid allopregnanolone in the VTA) in intact animals is inhibitory through its access to the VMN. Indeed, i.c.v. injection of antiserum against allopregnanolone during proestrus augments lordosis (Genazzani et al, 1995) . Thus, female sexual behavior may be a product of facilitation by progesterone and disinhibition by serum-derived and possibly locally synthesized allopregnanolone in the VMN while in the VTA where the progesterone receptor is absent, neurosteroid allopregnanolone augments VMN activity.
At the same time, systemic administration of high doses of allopregnanolone can induce lordosis by itself in estrogen-primed progesterone receptor-knockout OVX aged females (Frye et al, 2006b ). This observation implies that this steroid can rescue losses in receptivity with aging when progesterone receptor levels in the VMN are compromised due to reduced central allopregnanolone levels and neurons may have increased sensitivity to allopregnanolone and GABA A -channel activity (Genazzani et al, 2004) . A previous report noted that high doses of estrogen by itself also elicit lordosis independent of progesterone receptor action (Apostolakis et al, 2000) . It is possible then that estrogen can stimulate receptive behavior through changes in allopregnanolone production in the CNS.
Infusion of 5α-reduced androstanediol has similar paradoxical effects on lordosis and further promotes aggression in female rats, possibly through GABA A receptor inhibition in the medial preoptic area (POA) and VMN (Frye et al, 1996b; Frye et al, 1996a; Frye et al, 1996c) .
Neurosteroids are also implicated in mediating the preference for male odors by female rats and pheromone-stimulated release of GnRH and ovulation (More, 2006) . Therefore, neurosteroids may act at several points in the CNS to regulate sexual motivation and receptive behavior.
Male Sexual Behavior. Neurosteroids may also influence male sexual behavior through GABA A receptors. Allopregnanolone has been shown in male rats to potentiate GABA A channel activity in neurons in the medial POA, a region that also produces neurosteroids and is essential for sexual interest, erection, copulation, and ejaculation (Haage et al, 2005; Haage and Johansson, 1999; Uchida et al, 2002) . Pregnenolone sulfate opposes the effects of allopregnanolone.
Progesterone may also inhibit sexual behavior. Loss of the progesterone receptor or subcutaneous (s.c.) infusion of antiprogestin RU486 enhances mount and intromission frequency in the absence of changes in testosterone or testicular function (Schneider et al, 2005) . However, it is unclear in this case whether it is progesterone derived from the serum, from local synthesis in the CNS or in combination that is inhibitory.
On the other hand, estradiol rapidly induces copulatory behavior through actions in the medial POA and amygdala (Balthazart et al, 2004; Huddleston et al, 2003; Huddleston et al, 2006) . It is unclear if local synthesis of estrogen is involved; however, gonadal sources of this steroid including those generated from aromatization of testosterone in the brain are clearly critical for sexual behavior and maintenance of sensitivity for sexual stimulation.
Neurosteroids may also regulate sensitivity to odor cues relevant to male sexual interest.
Neurosteroids are generated in components of the vomeronasal pathway key for relaying stimulatory signals from the odors of estrus females to the POA and bed nucleus of the stria terminalis. Consistent with this observation, pheromone preference for estrus females by male rodents is enhanced by i.c.v. administration of 3αHP and reduced by pregnenolone sulfate (Kavaliers et al, 1994; Kavaliers and Kinsella, 1995) .
Other evidence for roles of neurosteroids in sexual and gender-typical behaviors comes from avian models. All of the enzymes necessary for neurosteroidogenesis including StAR are present in the adult and developing songbird (London et al, 2006; London and Schlinger, 2007) .
Sex-dependent differences in time and level of de novo estrogen synthesis in the brain determine the establishment of a key neuronal circuit for male song in the zebra finch independent of the presence of gonadal steroids (Wade and Arnold, 1996; Holloway and Clayton, 2001; Forlano et al, 2006) .
In the quail, melatonin-regulated diurnal changes in brain levels of the neurosteroid 7α-hydroxypregnenolone occur in males but not in females, resulting in correspondingly higher locomotor activity (Tsutsui et al, 2008) .
Neurosteroids, Anxiety and Depression in Sexual and Gender-typical Behaviors
Neurosteroids also affect anxiety, stress and mood, all of which strongly impact sexual behavior. 5α-reduced steroids allopregnanolone or THDOC have anxiolytic, analgesic and sedative effects in large part through GABA A receptors (Lambert et al, 2003) . Inhibition of 5α-reductase activity in the amygdala increases anxiety and depression (Verleye et al, 2005; Walf et al, 2006) . Declines in anxiety elicited by the anxiolytic drug etifoxine correlate with increased CNS levels of anxiolytic allopregnanolone in sham-operated and gonadectomized (GDX)/ADX rats (Verleye et al, 2005) . Serum levels of the steroid also rise upon treatment in the intact animals suggesting an additional contribution from peripheral sources. Similarly, anxiogenic drugs increase levels of anxiolytic steroids in the brain and the serum (Barbaccia et al, 1996b; Barbaccia et al, 1996a) .
Pregnenolone and its sulfate conjugate increase anxiety and oppose anxiolytic and sedative effects induced by benzodiazepines and alcohol (Meieran et al, 2004; Melchior and Ritzmann, 1994; Strous et al, 2006) . Lower doses (0.1 μg/kg vs. 1.0 μg/kg) of pregnenolone sulfate administered i.p. causes anxiolysis (Melchior and Ritzmann, 1994) , possibly reflecting in part conversion to anxiolytic allopregnanolone.
In women, libido is not clearly dependent on gonadal status, but relies more on psychological factors such as societal influences and depression (Avis et al, 2005) . Anxiolytic neurosteroids may therefore impact sexual interest. As with sexual receptivity, the effect of these neurosteroids at least as measured in rodents is site-specific. Inhibition of allopregnanolone production through infusion of the 5α-reductase inhibitor finasteride (Proscar) systemically or into the hippocampus increases social interactions of estrus females while the inhibitor decreases such interactions when put into the amygdala of receptive females (Rhodes and Frye, 2001; Walf et al, 2006) .
On the other hand, infusion of allopregnanolone into the VTA in diestrus raises social interactions in female rats along with paced mating behavior to levels similar to those observed in proestrus (Frye and Rhodes, 2007) . Infusion of allopregnanolone into other parts of the brain, the substantia nigra and the central gray, did not reproduce these effects. The changes observed in social activities associated with sexual behaviors in proestrus may therefore involve allopregnanolone generation in the brain elicited by ovarian steroids.
In this manner, neurosteroids are part of a larger role in mood and adaptation to stress.
Pregnenolone may improve mood, while anxiolytic DHEA is antidepressant (Strous et al, 2006) . Postpartum depression and anxiety may also involve anxiogenic neurosteroids as well as the actions of peripheral steroids on the CNS (Maayan et al, 2004; Maayan et al, 2005) .
In men, depression is an important factor in many cases of erectile dysfunction and thus, neurosteroids that affect depression may be involved. Some effects of neurosteroids in depression in the male also appear to be gender-dependent. Experiments using a postnatal stress model reveal a lower sensitivity of adult male rats to repeated exposures of i.c.v.-administered allopregnanolone than females as measured by anxiety-related behavior, like reduced grooming (Zimmerberg et al, 1999) .
Social isolation stress also reduces brain 5α-reductase and allopregnanolone levels in males in an androgen-dependent manner, causing increased aggressive behavior in a residentintruder test and increased contextual fear responses (Dong et al, 2001; Pinna et al, 2004; Pinna et al, 2005) . These changes are restricted to select neurons with outputs to the amygdala and BLA glutamatergic neurons in the amygdala, all of which can alter emotional responses (Agís-Balboa et al, 2007) .
Fluoxetine (Prozac) rescues the decline in allopregnanolone and change in aggressiveness (Pinna et al, 2003) .
Other experiments also link aggressiveness by male rodents to neurosteroids. Chronic treatment with DHEA inhibits aggressiveness by GDX male mice toward lactating female intruders and correlates with specific declines in measured pregnenolone sulfate levels in the brain (Young et al, 1991) . Inhibition of 3βHSD activity increases pregnenolone but not pregnenolone sulfate levels and also reduces belligerence (Young et al, 1996) . It is not clear that this change in behavior is simply due to lowered progesterone levels in the CNS. Progesterone receptor-knockout males only exhibit reduced aggressiveness towards infants not adult males while progesterone increases this aggressive behavior in wild-type mice (Schneider et al, 2003) .
Similar effects on behavior and pregnenolone sulfate levels by DHEA are reported for androgenized females . Androstanediol self-administration which results in higher CNS levels of the steroid also decreases aggressiveness and may be rewarding in male hamsters (Frye et al, 2006a) . Through mediating changes in psychological parameters such as anxiety and stress, neurosteroids may therefore have additional roles in regulating sexual interest and gender-typical behaviors.
The Future of Neurosteroids in the Clinic
Currently, neurosteroids are being developed as a part of palliative or therapeutic approaches to treat psychological disorders, addictive behaviors, neurological disorders and neurodegenerative conditions (Strous et al, 2006) . A synthetic form of allopregnanolone, ganaxolone, is in phase II trials for treating seizures (Nohria and Giller, 2007) . Neurosteroids can also be prophylactic against age-related changes in nervous system function. Treatments that directly target sexual and reproductive dysfunctions do not yet exist, although as indicated above, current gonadal replacement strategies to address problems of libido may act in part through the induction of local neurosteroid synthesis. Moreover, therapies that address other conditions such as mood disorders may positively impact sexual desire. Early experimental trials have met with mixed success (Strous et al, 2006; Uzunova et al, 2006) . Most notably, DHEA does not reliably improve mood in subjects treated with the steroid (Strous et al, 2006) .
One concern in the use of systemic steroidal therapies is that they not only alter neurosteroid levels in the target region of the brain but throughout the brain and the circulation, potentially resulting in adverse or opposing effects on other parts of the brain or on other tissues.
Whereas intrahippocampal administration of pregnenolone sulfate improves memory in aging rats, systemic administration may also increase belligerence among other effects (Vallée et al, 1997) . As well, certain neurosteroids can have differential effects on target cells depending on concentration and length of treatment.
A final consideration is that in the absence of lowered neurosteroid production, neurosteroid supplementation may not augment their activity. For instance, addition of estrogen to rat hippocampal neurons only supports cell survival and proliferation when endogenous estrogen synthesis is blocked (Fester et al, 2006) . This is an important consideration in the human since unlike in rodent models, clinical studies have yet to link depression to a deficiency in anti-depressive neurosteroids (Uzunova et al, 2006) . Consequently, neurosteroids are eyed as a novel treatment for diseases in which neurosteroid production is compromised, such as
Alzheimer's and Niemann-Pick type C (Wang et al, 2007; Griffin et al, 2004; Chen et al, 2007; Liu et al, 2008) . Their application can also assist in survival and remyelination of nerves damaged due to injury or disease (Schumacher et al, 2007 ).
An alternative approach is to use drugs that specifically increase neurosteroid concentrations. Antipsychotic agents clozapine and olanzapine may improve schizophrenia by increasing brain allopregnanolone synthesis (Marx et al, 2006) . Similarly, the reduction in aggression induced by fluoxetine may be directly due to increased allopregnanolone levels in the CNS since the drug is effective at levels ten-fold lower than those that block serotonin reuptake (Pinna et al, 2003) . Negative side effects of drugs may also be explained by neurosteroid modulation. Notably, preliminary studies indicate that as in the rodent, finasteride may increase depression in men as a result of the loss of allopregnanolone (e.g., Altomare et al, 2002; RahimiArdabili et al, 2006) . This raises the possibility that lowered levels of the neurosteroid contribute to the reduced sexual desire reported for some patients. Treatment strategies that take into account effects on neurosteroids and the development of drugs that singularly target neurosteroid biosynthesis may therefore provide superior therapies for patients.
Conclusion
The full role of neurosteroids in sexual behavior and reproduction is unclear.
Neurosteroids may also indirectly promote and preserve sexual function through roles in neuronal growth and development and neuroprotection in the CNS and PNS. Moreover, determination of which functions are truly governed by neurosteroids, neuroactive steroids generated from peripheral sources or a combination of the two is still under investigation. Future gains in the application of neurosteroids for the treatment of sexual dysfunctions necessitate a clearer delineation of the roles of these compounds in the nervous system and how they complement the influence of gonadal and adrenal steroids. 
